Table 1

Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012–2015

Sandra N. Bulens

, Sarah H. Yi, Maroya S. Walters, Jesse T. Jacob, Chris Bower, Jessica Reno, Lucy Wilson, Elisabeth Vaeth, Wendy Bamberg, Sarah J. Janelle, Ruth Lynfield, Paula Snippes Vagnone, Kristin Shaw, Marion Kainer, Daniel Muleta, Jacqueline Mounsey, Ghinwa Dumyati, Cathleen Concannon, Zintars Beldavs, P. Maureen Cassidy, Erin C. Phipps, Nicole Kenslow, Emily B. Hancock, and Alexander J. Kallen

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.N. Bulens, S.H. Yi, M.S. Walters, A.J. Kallen); Emory University School of Medicine, Atlanta (J.T. Jacob); Georgia Emerging Infections Program, Atlanta (J.T. Jacob, C. Bower, J. Reno); Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA (C. Bower, J. Reno); Atlanta Research and Education Foundation, Decatur (C. Bower, J. Reno); Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA (L. Wilson, E. Vaeth); Colorado Department of Public Health and Environment, Denver, Colorado, USA (W. Bamberg, S.J. Janelle); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield, P.S. Vagnone, K. Shaw); Tennessee Department of Public Health, Nashville, Tennessee, USA (M. Kainer, D. Muleta, J. Mounsey); New York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, USA (G. Dumyati, C. Concannon); Oregon Health Authority, Portland, Oregon, USA (Z. Beldavs, P.M. Cassidy); University of New Mexico, Albuquerque, New Mexico, USA (E.C. Phipps, N. Kenslow, E.B. Hancock)

Main Article

Case counts and incidence of carbapenem-nonsusceptiable Acinetobacter baumannii in Emerging Infections Program sites, United States, 2012–2015*

Area	No. cases, N = 621				Crude annual incidence rates‡ (95% CI)				aSIR‡ (95% CI)	aIR‡§ for all years
Area	2012†	2013	2014	2015	2012†	2013	2014	2015	aSIR‡ (95% CI)	aIR‡§ for all years
CO	NDND	11	7	8	ND	0.4 (0.2–0.8)	0.3 (0.1–0.6)	0.3 (0.1–0.6)	0.4 (0.3–0.6)	0.4
GA	111	78	47	64	2.9 (2.4–3.5)	2.0 (1.6–2.5)	1.2 (0.9–1.5)	1.6 (1.2–2.1)	1.2 (1.1–1.4)	1.2
MD	ND	77	81	78	ND	4.0 (3.2–5.0)	4.2 (3.3–5.2)	4.0 (3.2–5.0)	2.5 (2.2–2.9)	3.0
MN	2	10	7	7	0.12 (0–0.4)	0.6 (0.3–1.1)	0.4 (0.2–0.8)	0.4 (0.2–0.8)	0.4 (0.2–0.5)	0.4
NM	ND	0	1	1	ND	0 (0–0.4)	0.2 (0–0.8)	0.2 (0–0.8)	0.1 (0–0.4)	0.1
NY	ND	4	1	3	ND	0.5 (0.2–1.4)	0.1 (0–0.7)	0.4 (0.1–1.2)	0.3 (0.1–0.6)	0.4
OR	0	4	0	0	0 (0–0.2)	0.2 (0.1–0.6)	0 (0–0.2)	0 (0–0.2)	0.1 (0–0.1)	0.1
TN	ND	ND	12	7	ND	ND–	0.7 (0.4–1.3)	0.4 (0.2–0.9)	0.6 (0.4–1.0)	0.7
Total	113	184	156	168	1.6 (1.3–1.9)	1.4 (1.2–1.6)	1.0 (0.9–1.2)	1.1 (0.9–1.3)	ND–	ND–

*The study areas were Denver, CO; Atlanta, GA; Baltimore, MD; Minneapolis/Saint Paul, MN, Albuquerque, NM; Rochester, NY; Portland, OR; Nashville, TN. aIR, annual incidence rate; aSIR, adjusted standardized incidence ratio; ND, no data available.
†Only 3 Emerging Infection Program sites participated in 2012.
‡Per 100,000 population.
§Adjusted for age, race and sex.

Main Article

Page created: March 19, 2018

Page updated: March 19, 2018

Page reviewed: March 19, 2018

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.